REMISSION to Adult Acute Lymphoblastic Leukemia (ALL): Pfizer’s Sutent blocks FLT3 Gene Receptors | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« Mitochondria: More than just the “powerhouse of the cell”

Pfizer’s Kidney Cancer Drug Sutent Effectively caused REMISSION to Adult Acute Lymphoblastic Leukemia (ALL) »

REMISSION to Adult Acute Lymphoblastic Leukemia (ALL): Pfizer’s Sutent blocks FLT3 Gene Receptors

July 10, 2012 by 2012pharmaceutical

Curator: Aviva Lev-Ari, PhD, RN

Sunitinib brings Adult acute lymphoblastic leukemia (ALL) to Remission – RNA Sequencing – FLT3 Receptor Blockade

https://pharmaceuticalintelligence.com/2012/07/09/sunitinib-brings-adult-all-to-remission-rna-sequencing/

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Genome Biology | Tagged DNA Sequencing, FLT3 gene on CHromosome 13, FLT3 receptor blockage, Pfizer, RNA sequencing, Suntinib, Sutent | 2 Comments

2 Responses

on January 13, 2013 at 5:38 PM | Reply LEADERS in Genome Sequencing of Genetic Mutations for Therapeutic Drug Selection in Cancer Personalized Treatment: Part 2 « Pharmaceutical Intelligence

[…] REMISSION to Adult Acute Lymphoblastic Leukemia (ALL): Pfizer’s Sutent blocks FLT3 Gene Receptors […]
on April 20, 2014 at 6:20 PM | Reply Cancer Research: Curations and Reporting: Aviva Lev-Ari, PhD, RN | Pharmaceutical Intelligence

[…] https://pharmaceuticalintelligence.com/2012/07/10/remission-to-adult-acute-lymphoblastic-leukemia-all… […]

Leave a Reply Cancel reply

Enter your comment here...

Fill in your details below or click an icon to log in:

Email (required) (Address never made public)

Name (required)

Website

You are commenting using your WordPress.com account. ( Log Out / Change )

You are commenting using your Twitter account. ( Log Out / Change )

You are commenting using your Facebook account. ( Log Out / Change )

You are commenting using your Google+ account. ( Log Out / Change )

Connecting to %s

%d bloggers like this: